Chemed (CHE) Common Equity (2009 - 2026)

Chemed has reported Common Equity for 18 years, with the latest figure at $848.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 28.24% year-over-year to $848.0 million; the trailing twelve-month figure through Mar 2026 stood at $848.0 million (down 28.24% YoY), and the FY2025 full-year result was $979.4 million, down 12.47% from the prior year.
• Common Equity for Q1 2026 stood at $848.0 million, down from $979.4 million in the prior quarter.
• The five-year high for Common Equity was $1.2 billion in Q3 2024, with the low at $666.7 million in Q1 2022.
• Average Common Equity over 5 years is $991.8 million, with a median of $1.0 billion recorded in 2023.
• Year-over-year, Common Equity jumped 41.28% in 2023 and retreated 28.24% in 2026.
• Tracing CHE's Common Equity over 5 years: stood at $798.7 million in 2022, then surged by 38.71% to $1.1 billion in 2023, then advanced by 1.0% to $1.1 billion in 2024, then fell by 12.47% to $979.4 million in 2025, then retreated by 13.42% to $848.0 million in 2026.
• The last three Common Equity figures came in at $848.0 million (Q1 2026), $979.4 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison